The pet food industry is facing a pivotal moment as the demand for sustainable, high-protein alternatives grows. Leading this charge is Finnish biotech company Enifer, which is introducing its proprietary mycoprotein, PEKILO, into the commercial market. By transitioning from laboratory research to scalable production, Enifer is positioning mycoprotein as a viable, eco-friendly replacement for traditional animal proteins in pet nutrition.
What is PEKILO Mycoprotein?
PEKILO is a mycoprotein produced through biomass fermentation. Unlike traditional plant-based proteins, mycoprotein is derived from fungi, offering a nutritional profile that more closely mimics animal meat. This makes it an ideal candidate for pet foods, where high protein quality and specific amino acid profiles are non-negotiable for animal health.
One of the standout features of PEKILO is its nutrient density. The ingredient contains more than 60% protein and boasts an amino acid profile comparable to meat, ensuring that pets receive the essential building blocks required for muscle maintenance and overall vitality without the environmental footprint of industrial livestock farming.
The Rovio Partnership: Bringing Mycoprotein to Dog Treats
To validate the commercial application of PEKILO, Enifer has partnered with Rovio Pet Foods. Together, they have developed a semi-moist dog treat, marking the first time this mycoprotein has been integrated into a finished pet treat format.
The launch follows a rigorous 60-day dog feeding study designed to test the ingredient’s real-world performance. The results were positive, demonstrating:
- High Digestibility: The protein was easily processed by the canine digestive system.
- Strong Palatability: Dogs found the treats appealing, a critical factor for any new pet food ingredient.
- Digestive Health: The study showed no negative impact on stool quality.
- Functional Benefits: Early signals indicated positive effects on oxidative balance and immune activity.
Scaling Production: The Kantvik Facility
Innovation in the lab is only useful if it can be scaled. Enifer is addressing this by launching a commercial-scale biomass fermentation facility in Kantvik, Finland. This plant is designed to enable consistent production at scale, allowing the company to move from small samples to bulk customer deliveries.
According to CEO Simo Ellilä, the facility is a key milestone for cost optimization and operational stability. The flexibility of Enifer’s technology allows the use of different feedstocks, which reduces reliance on a single raw material source and increases the overall sustainability of the production cycle.
Beyond Pet Food: The Future of Human Nutrition
While the current focus is heavily weighted toward the European pet food market, Enifer’s ambitions extend far beyond dog treats. The company is already collaborating with global industry leaders to integrate PEKILO across various sectors:
- Aquafeed: Partnering with Skretting, the aquafeed division of Nutreco.
- Dairy: Collaborating with the dairy giant Valio.
- Commercial Pet Food: Working with industry giant Purina.
The long-term strategy involves expanding into human nutrition, with a particular focus on the North American market. By establishing PEKILO as a versatile ingredient, Enifer aims to disrupt the global protein supply chain and provide a scalable solution to food insecurity and environmental degradation.
Key Takeaways: Enifer’s Market Entry
| Feature | Detail |
|---|---|
| Core Product | PEKILO Mycoprotein (Biomass Fermentation) |
| Protein Content | Over 60% |
| Primary Application | Semi-moist dog treats (via Rovio Pet Foods) |
| Production Hub | Kantvik, Finland |
| Key Partners | Purina, Valio, Skretting |
Frequently Asked Questions
Is mycoprotein safe for dogs?
Yes. In a 60-day feeding study, PEKILO showed high digestibility and strong palatability with no negative effects on stool quality, suggesting it is a safe and effective protein source for dogs.
How does mycoprotein differ from plant-based protein?
While plant proteins (like soy or pea) are derived from plants, mycoprotein is grown via fermentation of fungi. This typically results in a more complete amino acid profile and a texture that more closely resembles meat.
When will this be available for humans?
Enifer is currently in discussions with customers regarding human nutrition, with a specific strategic focus on the North American market. While pet treats are the first commercial application, human-grade products are the ultimate goal.
As the global food system shifts toward more resilient and sustainable models, the integration of biomass fermentation into everyday products marks a significant step forward. Enifer’s move into the pet food market is not just about dog treats; it is a blueprint for how alternative proteins can scale to feed both pets and people.